-+ 0.00%
-+ 0.00%
-+ 0.00%

Recently, various innovative drugs have successively ushered in marketing and clinical breakthroughs, and the popularity of overseas licensing cooperation between domestic pharmaceutical companies has increased. Industry experts and pharmaceutical company leaders analyzed that future industry competition will no longer be limited to pipeline number competition. Source innovation capabilities, global patent layout, domestic and international commercial operations, and flexible business development asset operation strategies will become the core grippers for innovative pharmaceutical companies to get through the cycle.

Zhitongcaijing·08/17/2026 23:25:10
Listen to the news
Recently, various innovative drugs have successively ushered in marketing and clinical breakthroughs, and the popularity of overseas licensing cooperation between domestic pharmaceutical companies has increased. Industry experts and pharmaceutical company leaders analyzed that future industry competition will no longer be limited to pipeline number competition. Source innovation capabilities, global patent layout, domestic and international commercial operations, and flexible business development asset operation strategies will become the core grippers for innovative pharmaceutical companies to get through the cycle.